Recombinant Cynomolgus TNF RII/TNFRSF1B Fc Protein, CF

Recombinant Cynomolgus Monkey TNF RII/TNFRSF1B Fc Chimera (Catalog # 10377-TR) inhibits Recombinant Human TNF-alpha (Catalog # 210-TA) mediated cytotoxicity in the L-929 mouse fibroblast cells. The ED50 for this effect is 0.2-1.2 ng/mL in the presence of 0.25 ng/mL of Recombinant Human TNF-alpha.

2 μg/lane of Recombinant Cynomolgus Monkey TNF RII/TNFRSF1B Fc Chimera (Catalog # 10377-TR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 68-80 kDa and 136-160 kDa, respectively.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus TNF RII/TNFRSF1B Fc Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit the TNF-alpha mediated cytotoxicity in the L‑929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. Matthews, N. and M.L. Neale (1987) in Lymphokines and Interferons, A Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 221. The ED₅₀ for this effect is 0.2-1.2 ng/mL in the presence of 0.25 ng/mL of Recombinant Human TNF-alpha (Catalog # 210-TA).
• Source: Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey TNF RII/TNFRSF1B protein
  

  Cynomolgus Monkey TNF RII/TNFRSF1B (Leu23-Asp257) Accession # XP_005544817.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_005544817.1
• N-terminal Sequence: Leu23
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 36 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 68-80 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus TNF RII/TNFRSF1B Fc Protein, CF

• CD120b antigen
• CD120b
• Etanercept
• p75 TNF receptor
• p75TBPII
• p75TNFR
• soluble TNFR1B variant 1
• TNF RII
• TNFBRp80 TNF-alpha receptor
• TNF-R2
• TNFR2TNFR1B
• TNF-R75
• TNFR80
• TNFRII
• TNF-RII
• TNF-R-II
• TNFR-II
• TNFRSF1B
• tumor necrosis factor beta receptor
• tumor necrosis factor binding protein 2
• Tumor necrosis factor receptor 2
• tumor necrosis factor receptor superfamily member 1B
• tumor necrosis factor receptor superfamily, member 1B
• Tumor necrosis factor receptor type II

Background

Tumor Necrosis Factor Receptor II (TNF RII), also known as TNFRSF1B, p75/p80, and CD120b, is a type I transmembrane protein that belongs to the TNF receptor superfamily (1-4). The TNF receptor superfamily is comprised of structurally related receptors that bind to TNF-related ligands and regulate numerous processes such as immune cell activation and apoptosis. Receptors in this superfamily are characterized by the presence of a cysteine-rich region in their extracellular domain (ECD) (1-3, 5). Cynomolgus monkey TNF RII shares 97% sequence identity in the ECD with its human homolog. Several receptors in the TNF superfamily also contain intracellular death domains (DDs) that recruit caspase-interacting proteins to initiate apoptosis upon ligand binding. Those receptors that lack DDs, like TNF RII, bind TNF Receptor-associated Factors, which transduce signals generated by activation of these receptors (6, 7). TNF RII is expressed predominantly on cells of the hematopoietic lineage, such as T and natural killer cells, as well as on endothelial cells, microglia, astrocytes, neurons, oligodendrocytes, cardiac myocytes, and thymocytes (6, 8, 9). TNF RII activation primarily initiates pro-inflammatory and pro-survival responses via NF kappa B-dependent signaling pathways (6, 7). However, under certain conditions, TNF RII signaling can induce apoptosis (8). Soluble TNF RII is believed to inhibit TNF biological activity by binding TNF thereby preventing it from activating membrane TNF receptors (10).

1. Dembic, Z. et al. (1990) Cytokine 2:231.
2. Kohno, T. et al. (1990) Proc. Natl. Acad. Sci. USA 87:8331.
3. Lewis, M. et al. (1991) Proc. Natl. Acad. Sci. USA 88:2830.
4. Loetscher, H. et al. (1990) J. Biol. Chem. 265:20131.
5. Beltinger, C.P. et al. (1996) Genomics 35:94.
6. Faustman, D. and M. Davis (2010) Nat. Rev. Drug Discov. 9:482.
7. Ihnatko, R. and M. Kubeš (2007) Gen. Physiol. Biophys. 26:159.
8. Mason, A.T. et al. (1995) J. Leukoc. Biol. 58:249.
9. Speeckaert, M.M. et al. (2012) Am. J. Nephrol. 36:261.
10. Sennikov, S.V. et al. (2014) Mediators Inflamm. 2014:745909.

Bioinformatics

• Uniprot:
  • XP_005544817.1()